How many clinical trials are tracked of leflunomide?

15 trials are tracked, 8 with published results.

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Questions

Text Size

leflunomide

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of leflunomide

15 trials tracked of leflunomide: 11 in phase 3 or 4 and 8 with published results. The most-cited published study has 210 citations.

15Trials tracked

11Phase 3 & 4

0Recruiting

8With published results

Phase distribution

Phase 4 5 Phase 3 6 Phase 2 3 Other / NA 1

Phase 3 To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) Completed · 210 cited
Phase 4 Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis. Completed · 128 cited
Phase 3 To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) Completed · 124 cited
Phase 4 IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA Completed · 70 cited
Phase 3 A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis Completed · 37 cited
Phase 3 To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis Completed · 28 cited

Show 9 more trials

Phase 4 Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial Completed · 3 cited
Phase 4 Psoriatic Oligoarthritis Intervention With Symptomatic thErapy Completed · 2 cited
Phase 4 Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis Completed
Phase 3 A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA) Completed
Phase 3 Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis Completed
Phase 2 Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Completed
Phase 2 Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed
Phase 2 Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders Completed
N/A Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood Completed

Showing the 15 most-cited and recently-updated of 15 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.